Life Science Innovation: Who Should Pay?
Is Business Broken?
Pricing Challenges in Innovative Therapies
This chapter examines the intricate challenges of pricing novel therapies in the life sciences, focusing on manufacturing costs and regulatory influences, particularly from the FDA. It discusses the potential shift to a single-payer healthcare model and its implications for access to cutting-edge treatments like gene and cell therapies. The conversation highlights international market dynamics and the ongoing impact of healthcare funding on innovation, particularly in response to the opioid crisis and access disparities.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
